US 12,168,008 B2
Oxabicycloheptanes for modulation of immune response
John S. Kovach, Pasadena, CA (US); Zhengping Zhuang, Bethesda, MD (US); Sze Chun Winson Ho, Bethesda, MD (US); Herui Wang, Bethesda, MD (US); and Rongze Lu, Sunnyvale, CA (US)
Assigned to Lixte Biotechnology, Inc., Pasadena, CA (US); and The United States of America, as Represented by the Secretary Department of Health and Human Services, Bethesda, MD (US)
Appl. No. 16/467,721
Filed by LIXTE BIOTECHNOLOGY, INC., Pasadena, CA (US); and THE UNITED STATES OF AMERICA, as Represented by the Secretary, Bethesda, MD (US)
PCT Filed Dec. 8, 2017, PCT No. PCT/US2017/065270
§ 371(c)(1), (2) Date Jun. 7, 2019,
PCT Pub. No. WO2018/107004, PCT Pub. Date Jun. 14, 2018.
Claims priority of provisional application 62/545,373, filed on Aug. 14, 2017.
Claims priority of provisional application 62/465,001, filed on Feb. 28, 2017.
Claims priority of provisional application 62/497,949, filed on Dec. 8, 2016.
Prior Publication US 2020/0069680 A1, Mar. 5, 2020
Int. Cl. A61K 39/395 (2006.01); A61K 9/00 (2006.01); A61K 31/496 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 31/496 (2013.01) [A61K 9/0019 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01)] 35 Claims
 
1. A method of treating a subject afflicted with cancer, comprising administering to the subject a 0.5 mg/m2, 0.83 mg/m2, 1.25 mg/m2, 1.75 mg/m2, or 2.33 mg/m2 dose of LB-100 or a salt thereof and a 1 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg, 5 mg/kg, 6 mg/kg, 7 mg/kg, 8 mg/kg, 9 mg/kg, or 10 mg/kg dose of an anti-programmed cell death protein-1 (anti-PD-1) antibody, wherein the LB-100 or salt thereof and the anti-PD-1 antibody are synergistically effective to treat the subject, wherein the treating is inducing inhibition, regression, or stasis of the cancer, and wherein the cancer is melanoma, colorectal cancer or glioblastoma.